- Parties: The plaintiffs were Lundbeck Canada Inc. and H. Lundbeck A/S. The defendant was Laboratoire Riva Inc.

- Subject Matter: This Federal Court matter involves an action under the Patented Medicines Regulations in which the patentees of TRINTELLIX® seek declarations of infringement and related relief regarding a proposed generic vortioxetine hydrobromide product. The case is ongoing.

- Date: The hearing was set on March 03, 2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.